32,000 stock options granted to Boundless Bio (BOLD) director

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Boundless Bio, Inc. director Jennifer Lew received a grant of stock options covering 32,000 shares of common stock. The options have an exercise price of $1.4000 per share and expire on June 14, 2036. They vest in substantially equal monthly installments over the 12 months following June 15, 2026, or in full on the date of the next annual stockholder meeting if it occurs before June 15, 2027, subject to her continued board service. This is a compensation-related award and does not involve any open-market buying or selling of shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lew Jennifer

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	32,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 32,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 32,000 options Exercise price: $1.4000 per share Expiration date: June 14, 2036 +1 more

4 metrics

Options granted 32,000 options Stock option grant to director Jennifer Lew

Exercise price $1.4000 per share Exercise price for the 32,000 stock options

Expiration date June 14, 2036 Option expiration for this grant

Vesting period 12 months after June 15, 2026 Monthly vesting schedule, with potential earlier full vesting at next annual meeting

Key Terms

Stock Option (right to buy), grant/award acquisition, vesting, board of directors

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

vesting financial

"The stock option shall vest in substantially equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

board of directors financial

"subject to the reporting person's continuing service on the issuer's board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 07:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lew Jennifer

(Last)

(First)

(Middle)

C/O BOUNDLESS BIO, INC.

11099 NORTH TORREY PINES RD., STE 150

(Street)

LA JOLLA

CALIFORNIA

92037

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Boundless Bio, Inc. [ BOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$1.4	06/15/2026		A		32,000		⁽¹⁾	06/14/2036	Common Stock	32,000	$0	32,000	D

Explanation of Responses:

1. The stock option shall vest in substantially equal monthly installments over the 12 months following June 15, 2026 (or, in the event the next annual meeting of the issuer's stockholders occurs prior to June 15, 2027, any remaining unvested portion of the stock option will vest on the date of such annual meeting), subject to the reporting person's continuing service on the issuer's board of directors through such vesting date.

	/s/ Jessica Oien, Attorney-in-Fact for Jennifer Lew	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Boundless Bio (BOLD) report for Jennifer Lew?

Boundless Bio reported that director Jennifer Lew received a grant of stock options for 32,000 shares. These options are a compensation-related award, not an open-market trade, and give her the right to buy Boundless Bio common stock at a fixed exercise price.

How many Boundless Bio (BOLD) stock options were granted to Jennifer Lew and at what price?

Jennifer Lew was granted stock options on 32,000 shares of Boundless Bio common stock at an exercise price of $1.4000 per share. This means she can purchase shares at that price once the options vest and before they expire, if she chooses.

What is the vesting schedule for Jennifer Lew’s Boundless Bio (BOLD) stock options?

The 32,000 Boundless Bio stock options granted to Jennifer Lew vest in substantially equal monthly installments over the 12 months following June 15, 2026. Any remaining unvested portion vests at the next annual stockholder meeting before June 15, 2027, subject to continued board service.

When do Jennifer Lew’s Boundless Bio (BOLD) stock options expire?

Jennifer Lew’s Boundless Bio stock options expire on June 14, 2036. She may choose to exercise vested options any time before that expiration date, paying the $1.4000 exercise price per share if she decides to acquire the underlying common stock.

Did Jennifer Lew buy or sell Boundless Bio (BOLD) shares in the market in this Form 4?

No, this Form 4 shows a grant of stock options to Jennifer Lew as compensation. It does not report any open-market purchases or sales of Boundless Bio common stock; it only records the award of a right to buy shares in the future.

How many Boundless Bio (BOLD) options does Jennifer Lew hold after this transaction?

After this transaction, Jennifer Lew holds 32,000 stock options according to the filing. These options relate to Boundless Bio common stock, are exercisable at $1.4000 per share, and follow the specified vesting schedule and expiration date disclosed in the Form 4.